Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sigyn Therapeutics Inc (OP: SIGY )

0.1800 UNCHANGED
Last Price Updated: 3:45 PM EST, Nov 17, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.1800
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.1800
Today's Range 0.1800 - 0.1800
52wk Range 0.0520 - 0.4800
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sigyn Therapeutics Reports Third Quarter 2023 Financial Results
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Sigyn Therapeutics Discloses PCT Patent Submission to Enhance Chemotherapy Delivery and Reduce Cancer Treatment Toxicity
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Death Economy Intellectual Property
Exposures Death Intellectual Property Supply Chain

Performance

YTD
-18.18%
-18.18%
1 Month
N/A
N/A
3 Month
-33.33%
-33.33%
6 Month
+80.00%
+80.00%
1 Year
-27.97%
-27.97%

More News

Read More
Sigyn Therapeutics to Present at Today's Emerging Growth Conference and Tomorrow at the National Investment Bankers Association Conference
Via NewMediaWire
Sigyn Therapeutics Reports Second Quarter 2023 Financial Results
Via NewMediaWire
Sigyn Therapeutics to Present at Tomorrow's Emerging Growth Conference
Via NewMediaWire
OTCQB Venture Virtual Investor Conference: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
OTCQB Venture Virtual Investor Conference Agenda Announced for August 3rd
From Virtual Investor Conferences
Via GlobeNewswire
Sigyn Therapeutics to Present at the OTCQB Venture Virtual Investor Conference on August 3rd
From Virtual Investor Conferences
Via GlobeNewswire
Sigyn Therapeutics Discloses "DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES" Patent Submission and Related ImmunePrepTM Trademark Application
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
Sigyn Therapeutics Reports First Quarter 2023 Financial Results
Via NewMediaWire
Sigyn Therapeutics Announces Appointment of Annette Marleau, Ph.D. as Chief Scientific Officer
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Sigyn Therapeutics Announces Filing of 2022 Annual Report on SEC Form 10-K
Via NewMediaWire
Topics Regulatory Compliance
Exposures Legal Regulatory
Sigyn Therapeutics Announces Third Quarter 2022 Financial Results
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
Sigyn Therapeutics Discloses Trademark Applications to Register ChemoPrepTM and ChemoPureTM for Devices to Enhance Cancer Therapy
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
Sigyn Therapeutics Announces Cancer-Related Patent Submission Entitled: System and Methods to Enhance Chemotherapy Delivery and Reduce Toxicity
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
Sigyn Therapeutics Strengthens Board of Directors With the Appointments of Richa Nand, Jim Dorst and Christopher Wetzel
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
Sigyn Therapeutics Announces First-In-Human Clinical Strategy to Address Inflammation and Endotoxemia in End-Stage Renal Disease Patients
Via NewMediaWire
Topics Death
Exposures Death
Sigyn Therapeutics Announces Second Quarter 2022 Financial Results
Via NewMediaWire
Sigyn Therapeutics to Commence Trading on the OTCQB Venture Exchange
Via NewMediaWire
Sigyn Therapeutics Appoints Donald J. Hillebrand, M.D. to its Scientific Advisory Board
Via NewMediaWire
Topics Death
Exposures Death
Sigyn Therapeutics Appoints Ajay Verma, M.D., Ph.D. to Its Scientific Advisory Board
Via NewMediaWire
Sigyn Therapeutics Announces Filing of 2021 Annual Report on Form 10-K
Via NewMediaWire
Topics Death
Exposures Death
Sigyn Therapeutics Appoints H. David Humes, MD to Its Scientific Advisory Board
Via NewMediaWire
Sigyn Therapeutics Appoints Alexander S. Yevzlin, MD, FASN to Its Scientific Advisory Board
Via NewMediaWire
Topics Death
Exposures Death
Sigyn Therapeutics Appoints Accomplished Financial Executive, Jeremy Ferrell, as Chief Financial Officer
Via NewMediaWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.